Osteoarthritis — an untreatable disease?
暂无分享,去创建一个
Martin Michaelis | M. Michaelis | H. Wieland | Heike A. Wieland | Bernhard J. Kirschbaum | Karl A. Rudolphi | K. Rudolphi
[1] P. Cheras,et al. Vascular mechanisms in osteoarthritis. , 2001, Best practice & research. Clinical rheumatology.
[2] A. Yamaguchi,et al. A human chondrogenic cell line retains multi-potency that differentiates into osteoblasts and adipocytes. , 2004, Bone.
[3] D. Eyre,et al. The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis. , 2003, Arthritis and rheumatism.
[4] J. Vane,et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[5] A. Zien,et al. Functional genomics of osteoarthritis. , 2002, Pharmacogenomics.
[6] S. Petit-Zeman. Characteristics of COX2 inhibitors questioned , 2004, Nature Reviews Drug Discovery.
[7] J. Gimble,et al. Bone and fat , 2004, Endocrine.
[8] J. A. Cook,et al. Neurogenic acceleration of osteoarthritis. , 1998, Current opinion in rheumatology.
[9] P. Creamer. Intra-articular corticosteroid treatment in osteoarthritis. , 2000, Current opinion in rheumatology.
[10] S. Clarke,et al. Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over five years. , 2004, Arthritis and rheumatism.
[11] L. Duong,et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. , 2004, Arthritis and rheumatism.
[12] L. Sharma,et al. Quadriceps Strength and Osteoarthritis Progression in Malaligned and Lax Knees , 2004, Annals of Internal Medicine.
[13] Han,et al. Specific NF‐κB blockade selectively inhibits tumour necrosis factor‐α‐induced COX‐2 but not constitutive COX‐1 gene expression in HT‐29 cells , 1998, Immunology.
[14] Tomoyuki Saito,et al. Distribution of Neuropeptides in Synovium of the Knee With Osteoarthritis , 2000, Clinical orthopaedics and related research.
[15] L. Urbán,et al. Mechanisms of inflammatory pain. , 2001, British journal of anaesthesia.
[16] W. Zhang,et al. A historic issue of the Annals: three papers examine paracetamol in osteoarthritis , 2004, Annals of the rheumatic diseases.
[17] Adam Sapirstein,et al. Interleukin-1β-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity , 2001, Nature.
[18] S. Mazzuca,et al. Quadriceps Weakness and Osteoarthritis of the Knee , 1997, Annals of Internal Medicine.
[19] C. Woolf,et al. Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor α , 1997, British journal of pharmacology.
[20] T McAlindon,et al. Exercise for knee osteoarthritis , 2000, Current opinion in rheumatology.
[21] E. Badley,et al. Arthritis and the aging population: projections of arthritis prevalence in Canada 1991 to 2031. , 1998, The Journal of rheumatology.
[22] M. Dougados,et al. Intra-articular treatments in osteoarthritis: from the symptomatic to the structure modifying , 2004, Annals of the Rheumatic Diseases.
[23] G. Knutsen,et al. Human articular chondrocytes express functional leptin receptors. , 2001, Biochemical and biophysical research communications.
[24] M. Dougados,et al. The use of glucosamine therapy in osteoarthritis , 2004, Current rheumatology reports.
[25] Patricia Ducy,et al. Leptin Regulates Bone Formation via the Sympathetic Nervous System , 2002, Cell.
[26] K. Brandt,et al. Intraarticular injection of hyaluronan as treatment for knee osteoarthritis: what is the evidence? , 2000, Arthritis and rheumatism.
[27] D. Loeuille,et al. Evidence for a key role of leptin in osteoarthritis. , 2003, Arthritis and rheumatism.
[28] J. Wallace,et al. The therapeutic potential of NO‐NSAIDs , 2003, Fundamental & clinical pharmacology.
[29] T. Schnitzer,et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial , 2004, The Lancet.
[30] M. Hurley,et al. Sensorimotor changes and functional performance in patients with knee osteoarthritis , 1997, Annals of the rheumatic diseases.
[31] W. B. van den Berg,et al. The relation between cartilage damage and osteophyte size in a murine model for osteoarthritis in the knee. , 1996, Rheumatology international.
[32] Gerd Geisslinger,et al. Specific Inhibition of IκB Kinase Reduces Hyperalgesia in Inflammatory and Neuropathic Pain Models in Rats , 2004, The Journal of Neuroscience.
[33] B. Szebenyi,et al. Hereditary disorders mimicking and/or causing premature osteoarthritis. , 2000, Bailliere's best practice & research. Clinical rheumatology.
[34] P. Isakson,et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. , 1999, Mayo Clinic proceedings.
[35] A. Parker,et al. Expression profiling of metalloproteinases and their inhibitors in cartilage. , 2004, Arthritis and rheumatism.
[36] Richard M Aspden,et al. Osteoarthritis as a systemic disorder including stromal cell differentiation and lipid metabolism , 2001, The Lancet.
[37] H. Minehara,et al. Growth Factor Expression in the Osteophytes of the Human Femoral Head in Osteoarthritis , 2000, Clinical orthopaedics and related research.
[38] H. Schaible. Mechanisms of pain in arthritis , 2002, Annals of the New York Academy of Sciences.
[39] T. Schnitzer,et al. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. , 2004, Arthritis and rheumatism.
[40] H Brenner,et al. International variation in hip replacement rates , 2003, Annals of the rheumatic diseases.
[41] J. Reginster,et al. The inhibition of metalloproteinases to treat osteoarthritis: reality and new perspectives , 2002 .
[42] R. Flower. The development of COX2 inhibitors , 2003, Nature Reviews Drug Discovery.
[43] T. Spector,et al. Risk factors for osteoarthritis: genetics. , 2004, Osteoarthritis and cartilage.
[44] D. Felson,et al. Osteoarthritis: is it a disease of cartilage or of bone? , 2004, Arthritis and rheumatism.
[45] J. Magdalou,et al. Evidence for the Presence of Peroxisome Proliferator-activated Receptor (PPAR) α and γ and Retinoid Z Receptor in Cartilage , 2000, The Journal of Biological Chemistry.
[46] P. Halverson,et al. Calcium crystal-induced inflammation. , 2001, Current opinion in rheumatology.
[47] P. Tak,et al. Chemokines in joint disease: the key to inflammation? , 2004 .
[48] D. Lovinger,et al. Disruption of Endocannabinoid Release and Striatal Long-Term Depression by Postsynaptic Blockade of Endocannabinoid Membrane Transport , 2004, The Journal of Neuroscience.
[49] Y. Toda,et al. Change in body fat, but not body weight or metabolic correlates of obesity, is related to symptomatic relief of obese patients with knee osteoarthritis after a weight control program. , 1998, The Journal of rheumatology.
[50] S. Abramson,et al. Inflammation in osteoarthritis. , 2004, The Journal of rheumatology. Supplement.
[51] W. Buchanan,et al. Osteoarthritis: symptoms, signs and source of pain , 2004, InflammoPharmacology.
[52] P. Dieppe,et al. Pain mechanisms in osteoarthritis of the knee: effect of intraarticular anesthetic. , 1996, The Journal of rheumatology.
[53] C. Buckland-Wright. Subchondral bone changes in hand and knee osteoarthritis detected by radiography. , 2004, Osteoarthritis and cartilage.
[54] E. D. Harris. The bone and joint decade: a catalyst for progress. , 2001, Arthritis and rheumatism.
[55] J. Vane,et al. Cyclooxygenases 1 and 2. , 1998, Annual review of pharmacology and toxicology.
[56] S. Fuchs,et al. Differential induction and regulation of matrix metalloproteinases in osteoarthritic tissue and fluid synovial fibroblasts. , 2004, Osteoarthritis and cartilage.
[57] C. Woolf,et al. Contribution of interleukin‐1β to the inflammation‐induced increase in nerve growth factor levels and inflammatory hyperalgesia , 1995, British journal of pharmacology.
[58] J. Buckwalter,et al. The burden of musculoskeletal conditions at the start of the new millennium , 2003 .
[59] D. Walsh. Angiogenesis in osteoarthritis and spondylosis: successful repair with undesirable outcomes , 2004, Current opinion in rheumatology.
[60] M. Doherty,et al. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis?: a meta-analysis of randomised controlled trials , 2004, Annals of the rheumatic diseases.
[61] P. Dieppe,et al. Glucosamine for osteoarthritis: magic, hype, or confusion? , 2001, BMJ : British Medical Journal.
[62] Pascal Richette,et al. Peroxisome Proliferator-activated Receptor-γ Down-regulates Chondrocyte Matrix Metalloproteinase-1 via a Novel Composite Element* , 2004, Journal of Biological Chemistry.
[63] R. Zernicke,et al. Antiresorptive therapy conserves some periarticular bone and ligament mechanical properties after anterior cruciate ligament disruption in the rabbit knee , 2004, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[64] J. Pelletier. Rationale for the use of structure-modifying drugs and agents in the treatment of osteoarthritis. , 2004, Osteoarthritis and cartilage.
[65] J. Bolognese,et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. , 2000, Archives of internal medicine.
[66] M. Kress,et al. Involvement of the Proinflammatory Cytokines Tumor Necrosis Factor-α, IL-1β, and IL-6 But Not IL-8 in the Development of Heat Hyperalgesia: Effects on Heat-Evoked Calcitonin Gene-Related Peptide Release from Rat Skin , 2000, The Journal of Neuroscience.
[67] E. Kunkel. Systems biology in drug discovery , 2004, Nature Biotechnology.
[68] A. Jeng,et al. The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. , 2004, Current medicinal chemistry.
[69] D. Felson,et al. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. , 2000, JAMA.
[70] G. Firestein,et al. Expression and Regulation of Inducible IκB Kinase (IKK-i) in Human Fibroblast-like Synoviocytes , 2001 .
[71] Arndt F Schilling,et al. Leptin Inhibits Bone Formation through a Hypothalamic Relay A Central Control of Bone Mass , 2000, Cell.
[72] R. Loeser. Systemic and local regulation of articular cartilage metabolism: where does leptin fit in the puzzle? , 2003, Arthritis and rheumatism.
[73] K. Brandt,et al. Effects of a bisphosphonate on bone histomorphometry and dynamics in the canine cruciate deficiency model of osteoarthritis. , 1999, The Journal of rheumatology.
[74] L. Ryd,et al. Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double blind, placebo controlled multicentre trial. Hyaluronan Multicentre Trial Group. , 1996, Annals of the rheumatic diseases.
[75] Arden,et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT) , 2003, Annals of the rheumatic diseases.
[76] A. Freemont,et al. Mast cells in the synovium and synovial fluid in osteoarthritis. , 1993, British journal of rheumatology.
[77] C. Menkes,et al. Are osteophytes good or bad? , 2004, Osteoarthritis and cartilage.
[78] K. Mizumura. Natural history of nociceptor sensitization: the search for a peripheral mechanism of hyperalgesia , 1998 .
[79] Xiaoling Zhang,et al. Suppression of early experimental osteoarthritis by gene transfer of interleukin‐1 receptor antagonist and interleukin‐10 , 2004, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[80] K. Brune. Safety of anti-inflammatory treatment--new ways of thinking. , 2004, Rheumatology.
[81] Nih Consensus Panel. NIH Consensus Statement on total knee replacement December 8-10, 2003. , 2004 .
[82] W. B. van den Berg,et al. Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. , 2003, Osteoarthritis and cartilage.
[83] J. Vilensky,et al. Peripheral and central nervous system mechanisms of joint protection. , 2003, American journal of orthopedics.
[84] Leena Sharma,et al. The influence of alignment on risk of knee osteoarthritis progression according to baseline stage of disease. , 2002, Arthritis and rheumatism.
[85] A. Poole,et al. Biochemical/immunochemical biomarkers of osteoarthritis: utility for prediction of incident or progressive osteoarthritis. , 2003, Rheumatic diseases clinics of North America.
[86] Eric J Topol,et al. Failing the public health--rofecoxib, Merck, and the FDA. , 2004, The New England journal of medicine.
[87] P. Richette,et al. Structure-modifying agents for osteoarthritis: an update. , 2004, Joint, bone, spine : revue du rhumatisme.
[88] K D Brandt,et al. Osteophytes in osteoarthritis. Clinical aspects. , 1999, Osteoarthritis and cartilage.
[89] Michael Doherty,et al. Radiographic assessment of symptomatic knee osteoarthritis in the community: definitions and normal joint space , 1998, Annals of the rheumatic diseases.
[90] Thomas Aigner,et al. Articular cartilage and changes in Arthritis: Cell biology of osteoarthritis , 2001, Arthritis Research & Therapy.
[91] R. Meyer,et al. Pain and hyperalgesia after intradermal injection of bradykinin in humans , 1991, Clinical pharmacology and therapeutics.
[92] D. Felson,et al. Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. , 2003, JAMA.
[93] D. Lajeunesse. The role of bone in the treatment of osteoarthritis. , 2004, Osteoarthritis and cartilage.
[94] T. Aigner,et al. Regulation of anabolic and catabolic gene expression in normal and osteoarthritic adult human articular chondrocytes by osteogenic protein-1. , 2004, Clinical and experimental rheumatology.
[95] F. Awiszus,et al. Neuromuscular quadriceps dysfunction prior to osteoarthritis of the knee , 2004, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[96] J. Levine,et al. Mechanical sensitization of cutaneous C-fiber nociceptors by prostaglandin E2 in the rat , 1999, Neuroscience Letters.
[97] Innovation OR Stagnation. Challenge and Opportunity on the Critical Path to New Medical Products , 2004 .
[98] J. Pelletier,et al. Cyclooxygenase-2 and prostaglandins in articular tissues. , 2003, Seminars in arthritis and rheumatism.
[99] D. Walsh,et al. Osteoarthritis, angiogenesis and inflammation. , 2005, Rheumatology.
[100] D. Felson,et al. Analysis of the discordance between radiographic changes and knee pain in osteoarthritis of the knee. , 2000, The Journal of rheumatology.
[101] M. Grynpas,et al. Subchondral bone in osteoarthritis , 2007, Calcified Tissue International.
[102] P. Tak,et al. NF-kappa B regulation by I kappa B kinase in primary fibroblast-like synoviocytes. , 1999, Journal of immunology.
[103] David T Felson,et al. An update on the pathogenesis and epidemiology of osteoarthritis. , 2004, Radiologic clinics of North America.
[104] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[105] D. Chadwick,et al. Osteoarthritic joint pain , 2004 .
[106] M. Dougados,et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. , 2002, Arthritis and rheumatism.
[107] Tomohiro Kato,et al. Neoantigens in osteoarthritic cartilage. , 2004, Current opinion in rheumatology.
[108] J Dequeker,et al. Inverse relationship osteoarthritis-osteoporosis: what is the evidence? What are the consequences? , 1996, British journal of rheumatology.
[109] Cindy Farquhar,et al. 3 The Cochrane Library , 1996 .
[110] M. Doherty,et al. Public-access defibrillation and survival after out-of-hospital cardiac arrest* , 2004 .
[111] P. Tak,et al. NF-κB Regulation by IκB Kinase in Primary Fibroblast-Like Synoviocytes , 1999, The Journal of Immunology.
[112] B. Whittle. Cyclooxygenase and nitric oxide systems in the gut as therapeutic targets for safer anti-inflammatory drugs. , 2004, Current opinion in pharmacology.
[113] S. Lindblad,et al. Arthroscopic and immunohistologic characterization of knee joint synovitis in osteoarthritis. , 1987, Arthritis and rheumatism.
[114] X. Ayral. Injections in the treatment of osteoarthritis. , 2001, Best practice & research. Clinical rheumatology.
[115] J. Pelletier,et al. 15d-PGJ(2) is acting as a 'dual agent' on the regulation of COX-2 expression in human osteoarthritic chondrocytes. , 2002, Osteoarthritis and cartilage.
[116] L. A. Koman,et al. Acute Pain Following Musculoskeletal Injuries and Orthopaedic Surgery , 2004 .
[117] P. Mapp. Innervation of the synovium. , 1995, Annals of the rheumatic diseases.
[118] F. Berenbaum. Signaling transduction: target in osteoarthritis , 2004, Current opinion in rheumatology.